+

WO1991006866A3 - Antigene associe a des tumeurs urinaires, emplois de sous-unites antigeniques et procedes de detection - Google Patents

Antigene associe a des tumeurs urinaires, emplois de sous-unites antigeniques et procedes de detection Download PDF

Info

Publication number
WO1991006866A3
WO1991006866A3 PCT/US1990/006339 US9006339W WO9106866A3 WO 1991006866 A3 WO1991006866 A3 WO 1991006866A3 US 9006339 W US9006339 W US 9006339W WO 9106866 A3 WO9106866 A3 WO 9106866A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
associated antigen
tumor associated
urinary tumor
detection
Prior art date
Application number
PCT/US1990/006339
Other languages
English (en)
Other versions
WO1991006866A2 (fr
Inventor
Donald L Morton
Rishab K Gupta
David M Euhus
Original Assignee
Donald L Morton
Rishab K Gupta
David M Euhus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23712351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1991006866(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Donald L Morton, Rishab K Gupta, David M Euhus filed Critical Donald L Morton
Priority to JP50047091A priority Critical patent/JP3423306B2/ja
Priority to CA002072620A priority patent/CA2072620C/fr
Priority to EP90917644A priority patent/EP0498851B1/fr
Priority to AU68753/91A priority patent/AU661816B2/en
Priority to DE69024659T priority patent/DE69024659T2/de
Publication of WO1991006866A2 publication Critical patent/WO1991006866A2/fr
Publication of WO1991006866A3 publication Critical patent/WO1991006866A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Polypeptide antigénique purifié d'antigène associé à des tumeurs urinaires ayant, après réduction par β-mercaptoéthanol et séparation par électrophorèse par gel SDS-polyacrylamide, une masse moléculaire comprise entre environ 90 et 100 kD. On décrit également des anticorps monoclonaux, des procédés de détection de cancers, des procédés d'immunothérapie, des procédés de contrôle d'une malignité, un procédé de détection d'antigène associé à des tumeurs urinaires, des vaccins contre les cellules tumorales ou un vaccin polypeptidique ainsi que d'autres procédés relatifs à l'antigène associé à des tumeurs urinaires.
PCT/US1990/006339 1989-11-03 1990-10-31 Antigene associe a des tumeurs urinaires, emplois de sous-unites antigeniques et procedes de detection WO1991006866A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP50047091A JP3423306B2 (ja) 1989-11-03 1990-10-31 尿中腫瘍関連抗原、抗原性サブユニットの使用および検出方法
CA002072620A CA2072620C (fr) 1989-11-03 1990-10-31 Antigene lie a une tumeur urinaire, utilisations de sous-unites antigeniques et methodes de detection
EP90917644A EP0498851B1 (fr) 1989-11-03 1990-10-31 Antigene associe a des tumeurs urinaires, emplois de sous-unites antigeniques et procedes de detection
AU68753/91A AU661816B2 (en) 1989-11-03 1990-10-31 Urinary tumor associated antigen, antigenic subunits uses and methods of detection
DE69024659T DE69024659T2 (de) 1989-11-03 1990-10-31 Harnwegstumor-assoziiertes antigen, verwendung von antigenen untereinheiten und nachweisverfahren

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43153389A 1989-11-03 1989-11-03
US431,533 1989-11-03

Publications (2)

Publication Number Publication Date
WO1991006866A2 WO1991006866A2 (fr) 1991-05-16
WO1991006866A3 true WO1991006866A3 (fr) 1991-09-05

Family

ID=23712351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/006339 WO1991006866A2 (fr) 1989-11-03 1990-10-31 Antigene associe a des tumeurs urinaires, emplois de sous-unites antigeniques et procedes de detection

Country Status (10)

Country Link
US (2) US5700649A (fr)
EP (2) EP0498851B1 (fr)
JP (2) JP3423306B2 (fr)
AT (2) ATE132629T1 (fr)
AU (1) AU661816B2 (fr)
CA (2) CA2072620C (fr)
DE (2) DE69024659T2 (fr)
DK (1) DK0498851T3 (fr)
ES (2) ES2138102T3 (fr)
WO (1) WO1991006866A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044421C (fr) * 1990-11-27 2005-06-21 Thomas Hyatt Duffy Antigene immunoreactif isole dans l'urine de la femme qui ressemble a l'antigene associe a l'epithelioma spinocellulaire
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
GB9806104D0 (en) * 1998-03-20 1998-05-20 Smithkline Beecham Biolog Novel compounds
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
CA2405363A1 (fr) 2000-04-28 2001-11-08 Ctl Immunotherapies Corp. Synchronisation d'epitopes dans des cellules presentant des antigenes
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
EP1752160A3 (fr) 2001-04-06 2007-05-30 Mannkind Corporation Sequences d'epitopes
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
EP2131198B1 (fr) 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Mesure des anticorps thérapeutiques, des antigènes et des complexes antigène/anticorps circulants à l'aide d'analyse ELISA
EP1453471B1 (fr) * 2001-11-07 2011-01-05 Mannkind Corporation Vecteurs d'expression codant pour des epitopes d'antigenes et procedes permettant leur conception
US20040029135A1 (en) * 2001-12-14 2004-02-12 Ramberg Elliot R. Diagnostic assays for BCWA
US20040180354A1 (en) * 2002-09-06 2004-09-16 Simard John J.L. Epitope sequences
GB2424273B (en) * 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
CN101146550B (zh) * 2004-12-29 2013-04-17 曼康公司 免疫原性组合物用于制备引发和增强免疫应答的试剂盒的用途
WO2007112316A2 (fr) * 2006-03-24 2007-10-04 Morton Donald L Immunothérapie mycobactérienne destinée au traitement du cancer
WO2008013912A1 (fr) * 2006-07-28 2008-01-31 Novartis Ag Utilisation d'une protéine d'inhibition de l'activité d'un mélanome (mia) en tant qu'indicateur précoce d'une réponse thérapeutique dans un mélanome
EP3084445B1 (fr) 2013-12-11 2020-10-28 University of Massachusetts Compositions et procédés de traitement d'une maladie au moyen d'une protéine effectrice t3ss de salmonella (sipa)
JP7097100B2 (ja) 2018-03-16 2022-07-07 Ｋｏｔａｉバイオテクノロジーズ株式会社 免疫実体の効率的クラスタリング

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2140030A (en) * 1983-04-08 1984-11-21 Kureha Chemical Ind Co Ltd Monoclonal antibody to human urinary bladder cancer
US4562160A (en) * 1983-04-01 1985-12-31 Sloan-Kettering Institute Melanoma tumor antigen and autologous antibody
GB2188637A (en) * 1986-02-07 1987-10-07 Oncogen Vaccines against melanoma
US4806628A (en) * 1982-11-30 1989-02-21 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies against melanocytes
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
EP0306995A2 (fr) * 1987-09-10 1989-03-15 Oncogen Limited Partnership Immunothérapie pour les tumeurs par utilisation d'anticorps anti-idiotypiques

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1603406A (en) * 1977-08-31 1981-11-25 Nat Res Dev Assay of immune complexes
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS5915858A (ja) * 1982-07-16 1984-01-26 Otsuka Pharmaceut Co Ltd 腫瘍関連抗原特異的免疫複合体の測定法
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
US4753884A (en) * 1986-01-28 1988-06-28 Novagene, Inc. Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
US5292636A (en) * 1986-03-31 1994-03-08 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using soluble T cell surface molecules
US4895817A (en) * 1986-05-09 1990-01-23 The Goodyear Tire & Rubber Company Polycondensation catalyst
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5194384A (en) * 1987-04-23 1993-03-16 Bystryn Jean Claude Method for preparing human meloma vaccine
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US4946774A (en) * 1987-11-09 1990-08-07 Trustees Of Boston University Process for detecting cancer and for monitoring the effectiveness of cancer therapy
US5250297A (en) * 1989-10-20 1993-10-05 Hybritech Incorporated Tumor-associated antigen, antibodies, compositions and uses therefor
US5427664A (en) * 1993-07-22 1995-06-27 Stoev; Stoyan V. Free solution electrophoresis-membrane filters trapping assay apparatus and method
DE69533295T3 (de) * 1994-02-16 2009-07-16 The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806628A (en) * 1982-11-30 1989-02-21 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies against melanocytes
US4562160A (en) * 1983-04-01 1985-12-31 Sloan-Kettering Institute Melanoma tumor antigen and autologous antibody
GB2140030A (en) * 1983-04-08 1984-11-21 Kureha Chemical Ind Co Ltd Monoclonal antibody to human urinary bladder cancer
GB2188637A (en) * 1986-02-07 1987-10-07 Oncogen Vaccines against melanoma
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
EP0306995A2 (fr) * 1987-09-10 1989-03-15 Oncogen Limited Partnership Immunothérapie pour les tumeurs par utilisation d'anticorps anti-idiotypiques

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
Cancer Immunol Immunother, Vol. 17, 1984, Paulie, S et al.: "Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder", page 173-179. *
Cancer Immunol Immunother, Vol. 29, 1989, David M. Euhus et al.: "Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine", page 247-254. *
Cancer Research, Vol. 45, 1985, Deborah A. Young et al.: "Production and Characterization of Mouse Monoclonal Antibodies to Human Bladder Tumor-associated Antigens", page 4439-4446. *
Cancer Research, Vol. 49, 1989, Duan-sun Zhang et al.: "Immunochemical and Biochemical Charaterizations of two Monoclonal Antibodyreacting Antigens Associated with Human Bladder Carcinoma", page 6621-6628. *
Chemical Abstracts, volume 94, No. 3, 19 January 1981, (Columbus, Ohio, US), Dippold, Wolfgang G et al.: "Cell surface antigens of human malignant melanoma: Definition of six antigenic systems with mouse monoclonal antibodies ", page 292, abstract 13890f, & Proc. Natl. Acad. Sci. U.S.A, 1980, 77(10), 6114-6118 *
Chemical Abstracts, volume 95, no. 11, 14 September 1981, (Columbus, Ohio, US), Brown, Joseph P et al.: "Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies", page 449, abstract 95294x, & J.Immunol 1981, 127( 2), 539-546. *
CRC Critical reviews in immunology, Vol. 5, No. 1, 1984, R.A. Reisfeld: "Human tumor-associated antigens defined by monoclonal antibodies", page 27-53. *
Dialog Information Service, File 159, Cancerlit, accession no. 00714302, Hopman AH et al: "Detection of numerical chromosome aberrations in bladder cancer by in situ hybridization", & Am J Pathol, 135(6):1105-17. *
Dialog Information Service, File 159, Cancerlit, accession no. 0330339, Gupta RK et al: "Immunologic similarity between tumor-associated antigens detected in urine of melanoma patients and those expressed by melanoma cells", & Proc Annu Meet Am Soc Clin Oncol, 3:9. *
Dialog Information Service, file 159, Cancerlit, accession no. 0584557, Hopman AH et al: "In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors", & Histochemistry, 89(4):307-16. *
Dialog Information Service, File 159, Cancerlit, accession no. 0635287, Doneda L et al: "In situ hybridization analysis of interstitial C-Heterochro-matin in marker chromosomes of two human melanomas", & Cancer Res, 49(2): 433-8. *
Hum Genet, Vol. 72, 1986, Michelle M. Le Beau et al.: "Chromosomal sublocalization of the human p97 melanoma antigen", page 294-296. *
Int. J. Cancer, Vol. 26, 1980, N.S. Rote et al.: "Determination of incidence and partial characterization of tumor-associated antigens found in the urine of patients bearing solid tumors", page 203-210. *
Journal of Biological Response Modifiers, Vol. 5, 1986, Jean-Claude Bystryn et al.: "Preparation and Characterization of a Polyvalent Human Melanoma Antigen Vaccine", page 221-224. *
Journal of Clinical Laboratory Analysis, Vol. 3, 1989, David M. Euhus et al.: "Detection of a Tumor-Associated Glycoprotein Antigen in Serum and Urine of Melanoma Patients by Murine Monoclonal Antibody(AD1-40F4) in Enzyme Immunoassay ", page 184-190. *
Molecular Immunology, Vol. 24, No. 1, 1987, Shuen-Kuei Liao et al.: "Difference in cell binding patterns of two monoclonal antibodies recognizing distinct epitopes on a human melanoma-associated oncofetal antigen", page 1-9 *
Science, Vol. 245, August 1989, Marx J.L.: "Cancer Vaccines Show Promise at Last", page 813-815. *

Also Published As

Publication number Publication date
JP3423306B2 (ja) 2003-07-07
DE69033295T2 (de) 2000-05-25
ATE132629T1 (de) 1996-01-15
CA2072620C (fr) 2007-06-12
AU6875391A (en) 1991-05-31
EP0678744B1 (fr) 1999-09-15
ATE184704T1 (de) 1999-10-15
ES2084715T3 (es) 1996-05-16
EP0498851A1 (fr) 1992-08-19
JP3429281B2 (ja) 2003-07-22
JP2001281255A (ja) 2001-10-10
US5993828A (en) 1999-11-30
EP0498851B1 (fr) 1996-01-03
DE69033295D1 (de) 1999-10-21
WO1991006866A2 (fr) 1991-05-16
CA2072620A1 (fr) 1991-05-04
EP0678744A2 (fr) 1995-10-25
EP0678744A3 (fr) 1995-12-13
DK0498851T3 (da) 1996-05-13
DE69024659D1 (de) 1996-02-15
CA2331088A1 (fr) 1991-05-04
DE69024659T2 (de) 1996-11-07
JPH05505596A (ja) 1993-08-19
US5700649A (en) 1997-12-23
ES2138102T3 (es) 2000-01-01
AU661816B2 (en) 1995-08-10

Similar Documents

Publication Publication Date Title
WO1991006866A3 (fr) Antigene associe a des tumeurs urinaires, emplois de sous-unites antigeniques et procedes de detection
WO1995029193A3 (fr) Antigenes du melanome
DK0942983T3 (da) Streptococcus pneumoniae-antigener og -vacciner
CA2047792A1 (fr) Peptides synthetiques specifiques pour la detection des anticorps diriges contre le vhc, diagnostic de l'infection a vhc et sa prevention grace a des vaccins
WO1996013593A3 (fr) Recepteurs de lymphocites t monocatenaires solubles
NZ296564A (en) Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides
WO1996021734A3 (fr) Antigenes p15 et tyrosinase du melanome et leur utilisation dans des procedes diagnostiques et therapeutiques
PL303482A1 (en) Vaccine against infection with streptococcus suis, streptococcus suis polypeptide and method of preparing such vaccine
FI950378A0 (fi) Immuunitesti kollageenin tai kollageenifragmenttien havaitsemiseksi
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
WO2000069915A3 (fr) APPROCHE COMBINEE AU TRAITEMENT DU CANCER AU MOYEN DE VACCINS D'hCG
DK185086D0 (da) Tumor-associeret antigen, antistoffer specifikke herfor samt fremgangsmaade til disses fremstilling
AU2032988A (en) A genus-specific listeria antigen identified by monoclonal antibodies
AU4803785A (en) Cross-reactive and protective epitopes of circumsporozoite proteins
IE860758L (en) Anaplasma marginale subunit antigen for vaccination and¹diagnosis
Hoessli et al. High molecular weight surface glycoproteins of murine lymphocytes.
WO1991017187A3 (fr) ANTIGENE PROTEIQUE ASSOCIE A UNE TUMEUR DE 35 kD: EMPLOIS ET PROCEDES DE DETECTION
ES2005569A6 (es) Metodos para detectar la presencia del organismo twar y sus anticuerpos en una muestra biologica.
KR930700850A (ko) 엠씨에이 28에이 32(m32)에 의해 인식되는 항원, 씨티에이에이 28에이 32(ct 28a32)
IL160387A0 (en) Antigen mimotopes and vaccine against cancers
Hammerl et al. Improvement of antisera raised against complex antigen mixtures by the use of heterologous sources of antigen for immunization
Westenbrink et al. Lack of evidence for non-virion cell surface antigens on virally-induced murine mammary tumor cells
DK340887A (da) Antigenisk peptid isoleret fra 28 kd proteinet fras. mansoni og fremgangsmaade til dets isolering, monoklonale antistoffer, der genkender mindst en epitop af peptidet og dets anvendelse til syntese af antistoffer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2072620

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990917644

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990917644

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990917644

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载